UCLA scientists test new strategy that could help fight ovarian cancer
UCLA scientists have developed a promising novel method to treat gynecologic tumors. The approach focuses on a protein called p53, which is commonly mutated in women who have high-grade serous ovarian cancer, the deadliest form of reproductive cancer. In many women with the disease, the cancer is very advanced by the time it is diagnosed and is therefore difficult to treat. The discovery was the result of a three-year study co-led by David Eisenberg and Dr. Sanaz Memarzadeh, members of the UCLA Jonsson Comprehensive Cancer Center. The findings, which were published online in the journal Cancer Cell, could ultimately lead to new targeted therapies for many other types of cancer carrying similar p53 mutations. P53 is known as the “guardian of the genome.” It prevents damaged cells from reproducing by stopping their growth until the damage is repaired or, if the damage cannot be reversed, promotes cell death. But mutations, which are found in 96 percent of patients with high-grade serous ovarian tumors, can cause p53 to form clumps, or “aggregates,” which impair the protein’s normal function. As a result, the damaged cells are able to multiply uncontrollably, which can lead to cancer. The UCLA scientists developed and tested a peptide called ReACp53, which penetrates cancer cells and prevents mutated p53 from clumping together. The technique restores normal p53 function, causing death of the ovarian cancer cells. “Our lab has worked for 15 yea...
Cancer Medicine, EarlyView.
ConclusionsIn our experience minimally invasive surgery is a valid therapeutic approach in very select patients with localized lymph-nodal recurrence of gynecological cancers, with benefits about peri and post-operative morbidities and without compromising their oncological outcome.
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer Interventions: Drug: Paclitaxel; Drug: Bevacizumab; Drug: Carboplatin; Drug: Placebo Sponsor: Hoffmann-La Roche Recruiting
FRIDAY, Aug. 17, 2018 -- Testing for gene mutations linked to breast and ovarian cancer is rare among some Medicare patients who have the cancers and qualify for such tests, a new study finds. Researchers analyzed data from 12 southeastern states...
Most woman are worried about the possible risks and complications of doing IVF treatment, but part of the problem is the many myths and misconceptions which plague IVF . Thus, it is clear that IVF doesn't increase the risk of birth defects and it won't cause breast cancer or ovarian cancer, but lots of websites continue to disseminate this misinformation.However, as with any other treatment, there are potential complications and this is why selecting a good IVF doctor is so important. One of the possible medical risks is that of ovarian hyper-stimulation syndrome ( OHSS), but in a well-managed clinic, this risk should...
Is population-based testing for breast and ovarian cancer gene mutations more cost-effective than family history-based BRCA testing?Journal of the National Cancer Institute
Contributors : Lan G Coffman ; Alex T Pearson ; Leonard G Frisbie ; Zackary Freeman ; Elizabeth L Christie ; David D Bowtell ; Ronald J BuckanovichSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCarcinoma-associated mesenchymal stem cells (CA-MSCs) are critical stromal progenitor cells within the tumor microenvironment. We previously demonstrated that CA-MSCs differentially express BMP genes, promote tumor cell growth, increase cancer ‘stemness’ and chemotherapy resistance. Here we use RNA sequencing of normal omental MSCs and ovarian CA-MSCs to demonstrate CA-MSCs have gl...
(University of Colorado Anschutz Medical Campus) Study shows that doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
This study not only details efficient methods to identify discriminative LMIs for cancer screening but also provides an example of metabolic profiling for distinguishing PC from BTC. Furthermore, the two metabolites [LysoPC(16:0), LysoPC(20:4)] shown to discriminate these diseases are potentially useful when combined with other, previously identified protein or metabolic biomarkers for predictive, preventive and personalized medical approach.
Conditions: Metastatic Ovarian Cancer; Triple Negative Breast Cancer Intervention: Biological: Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties. Sponsor: Immune System Key Ltd Not yet recruiting
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Chemotherapy | Computers | Health | Laboratory Medicine | National Institutes of Health (NIH) | Neurology | Neurosurgery | OBGYN | Ovarian Cancer | Ovaries | Stem Cell Therapy | Stem Cells | Study | Universities & Medical Training | Women